Amendment No. 1 to Amended and Restated Employment AgreementEmployment Agreement • February 23rd, 2023 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Amended and Restated Employment Agreement (this “Amendment No. 1”), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Kim C. Drapkin (the “Executive”).
CONSULTING AGREEMENTConsulting Agreement • February 23rd, 2023 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of February 22, 2023 and shall be effective at the close of business on the day that the Consultant’s employment with Jounce as a full-time, at-will employee terminates (such date, the “Effective Date”), by and between Richard Murray, Ph.D., an individual residing at [***] (hereinafter “Consultant”) and Jounce Therapeutics, Inc., a Delaware corporation, with its office located at 780 Memorial Drive, Cambridge, MA 02139 (hereinafter “Jounce”).
VOTING AND SUPPORT AGREEMENTVoting and Support Agreement • February 23rd, 2023 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This VOTING AND SUPPORT AGREEMENT (this “Agreement”), dated as of February __, 2023, is entered into by and among Redx Pharma plc, a publicly listed company organized in the United Kingdom (“Target”), Jounce Therapeutics, Inc., a Delaware corporation (“Parent”) and one or more persons set forth on Schedule A hereto (each, a “Stockholder” and, if applicable, collectively, the “Stockholders”). All terms used but not otherwise defined in this Agreement shall have the respective meanings ascribed to such terms in the announcement detailing the terms and conditions of the Merger to be made pursuant to Rule 2.7 of the City Code on Takeovers and Mergers (the “2.7 Announcement”).
AGREEMENT AND PLAN OF MERGER by and among JOUNCE THERAPEUTICS, INC., EVERGREEN MERGER SUB 1, LLC, and RM SPECIAL HOLDINGS 3, LLC Dated as of February 23, 2023Agreement and Plan of Merger • February 23rd, 2023 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This AGREEMENT AND PLAN OF MERGER, dated as of February 23, 2023 (this “Agreement”), is made and entered into by and among Jounce Therapeutics, Inc., a Delaware corporation (“Parent”), Evergreen Merger Sub 1, LLC, a Delaware limited liability company and a direct wholly owned subsidiary of Parent (“Merger Sub”), and RM Special Holdings 3, LLC, a Delaware limited liability company (the “Company”).
CONTENTS Clause Page 1. Definitions and interpretation ........................ ............................................................................ 1 2. Publication of the Announcement and the terms of the Transaction...Jounce Therapeutics, Inc. • February 23rd, 2023 • Biological products, (no disgnostic substances) • Delaware
Amendment No. 1 to Employment AgreementEmployment Agreement • February 23rd, 2023 • Jounce Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Employment Agreement (this “Amendment No. 1), effective January 27, 2023 (the “Amendment No. 1 Effective Date”), is made and entered into by and between Jounce Therapeutics, Inc., a Delaware corporation (“Jounce”), and Hugh Cole (the “Executive”).
